Atezolizumab in combination with bevacizumab is a promising first-line treatment option for people with unresectable hepatocellular carcinoma, ESMO 2019 delegates have heard. Presenting the results of the Phase 1b GO30140 study as a late breaking abstract Dr Michael Lee, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, said the ...
Promising results with dual blockade of PDL-1 and VEGF in unresectable HCC
By Nicola Garrett
28 Sep 2019